Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 51.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,429 shares of the medical equipment provider’s stock after selling 6,685 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Zimmer Biomet were worth $586,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. New Wave Wealth Advisors LLC boosted its holdings in Zimmer Biomet by 16.8% in the second quarter. New Wave Wealth Advisors LLC now owns 2,431 shares of the medical equipment provider’s stock worth $222,000 after purchasing an additional 349 shares during the period. Truist Financial Corp lifted its stake in Zimmer Biomet by 34.4% in the second quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider’s stock valued at $2,446,000 after buying an additional 6,867 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Zimmer Biomet by 37.0% in the second quarter. Janney Montgomery Scott LLC now owns 35,129 shares of the medical equipment provider’s stock valued at $3,204,000 after buying an additional 9,482 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in Zimmer Biomet by 3.4% in the second quarter. V Square Quantitative Management LLC now owns 5,972 shares of the medical equipment provider’s stock valued at $545,000 after buying an additional 194 shares during the last quarter. Finally, Uncommon Cents Investing LLC lifted its stake in Zimmer Biomet by 1.0% in the second quarter. Uncommon Cents Investing LLC now owns 20,903 shares of the medical equipment provider’s stock valued at $1,907,000 after buying an additional 212 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $100.81 on Friday. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The company’s 50-day moving average price is $100.87 and its two-hundred day moving average price is $98.71. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $114.72. The stock has a market cap of $19.97 billion, a PE ratio of 24.53, a price-to-earnings-growth ratio of 2.32 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.06 billion. During the same period in the previous year, the business earned $2.01 earnings per share. Zimmer Biomet’s revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s payout ratio is 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares in the company, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.39% of the company’s stock.

Analyst Ratings Changes

ZBH has been the topic of a number of recent research reports. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Rothschild Redb upgraded Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Royal Bank Of Canada upped their price objective on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Finally, Redburn Partners set a $130.00 target price on shares of Zimmer Biomet in a research report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $112.44.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.